



# Hemolysis in Pregnancy: Considerations for Sickle Cell Anemia Patients

**Emmanuel Ifeanyi Obeagu<sup>1\*</sup> and Getrude Uzoma Obeagu<sup>2</sup>**

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda

<sup>2</sup>School of Nursing Science, Kampala International University, Uganda

**\*Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com; obeagu.emmanuel@kiu.ac.ug

**Review Article**

**Volume 8 Issue 1**

**Received Date:** January 27, 2024

**Published Date:** February 15, 2024

**DOI:** 10.23880/hij-16000232

## Abstract

Hemolysis in pregnancy represents a complex and multifaceted challenge, particularly for individuals grappling with sickle cell anemia. This review delves into the intricate interplay between the physiological changes induced by pregnancy and the underlying pathophysiology of sickle cell anemia. It provides a comprehensive examination of the clinical implications, management strategies, and recent research advances pertaining to hemolysis in pregnant women with sickle cell anemia. The physiological adaptations inherent in pregnancy, including alterations in the cardiovascular and hematologic systems, create a dynamic environment that may exacerbate hemolysis in individuals with sickle cell anemia. This review elucidates the intricacies of these changes, establishing a foundation for understanding the heightened risks and challenges faced by pregnant women with this inherited blood disorder. Effective management strategies are crucial for optimizing outcomes in pregnant women with sickle cell anemia experiencing hemolysis. This review provides an in-depth analysis of various approaches, including the role of hydroxyurea therapy, blood transfusions, and meticulous monitoring of maternal and fetal parameters. By evaluating the potential benefits and risks of each strategy, clinicians are equipped with valuable insights to tailor interventions to individual patient needs. In conclusion, this comprehensive review offers a synthesized perspective on the considerations surrounding hemolysis in pregnancy for individuals with sickle cell anemia. Bridging the realms of physiology, clinical practice, and research, it provides a valuable resource for healthcare professionals, researchers, and policymakers seeking to enhance the care and outcomes of pregnant women grappling with sickle cell anemia and heightened hemolytic challenges.

**Keywords:** Hemolysis; Pregnancy; Sickle Cell Anemia; Physiological Changes; Maternal Health; Management Strategies

**Abbreviations:** IUGR: Intrauterine Growth Restriction; LDH: Lactate Dehydrogenase; VTE: Venous Thromboembolism; ACS: Acute Chest Syndrome; Hb: Hemoglobin.

## Introduction

Sickle cell anemia, a hereditary hemoglobinopathy characterized by the presence of abnormal hemoglobin S,

poses distinctive challenges during pregnancy. Hemolysis, the premature destruction of red blood cells, assumes a critical role in shaping the clinical landscape for pregnant women with sickle cell anemia. The intersection of pregnancy-induced physiological changes and the inherent pathophysiology of sickle cell anemia create a complex environment that demands a nuanced understanding and tailored management approaches [01-12]. Pregnancy induces a cascade of physiological adaptations aimed at supporting fetal development, affecting systems such as the cardiovascular and hematologic systems. In the context of sickle cell anemia, these changes may exacerbate hemolysis, heightening the risk of complications for both mother and fetus [13-22]. This review seeks to unravel the intricacies of this delicate balance, providing a comprehensive exploration of the considerations associated with hemolysis in pregnant women with sickle cell anemia.

The physiological adaptations in pregnancy, such as increased blood volume, changes in hormonal levels, and alterations in coagulation parameters, may amplify the challenges posed by sickle cell anemia. Understanding these changes is pivotal in deciphering the mechanisms that drive increased hemolysis and the subsequent clinical implications for both maternal and fetal well-being [23-32]. Clinically, hemolysis in pregnancy for individuals with sickle cell anemia introduces a myriad of challenges, including an elevated risk of vaso-occlusive crises, anemia, and a predisposition to thrombotic events. These complications can impact the course of the pregnancy, necessitating a vigilant and individualized approach to care. An exploration of the clinical landscape provides crucial insights into the risks associated with hemolysis, informing clinicians and healthcare providers about potential complications that may arise during the gestational period [33-42]. Effective management strategies are paramount in mitigating the risks associated with hemolysis in pregnant women with sickle cell anemia. This includes a careful evaluation of therapeutic options such as hydroxyurea, blood transfusions, and close monitoring of maternal and fetal parameters. The review aims to unravel the nuances of each approach, equipping healthcare professionals with the knowledge to make informed decisions tailored to the specific needs of each patient [43-52].

### Physiological Changes in Pregnancy

Pregnancy is a remarkable physiological journey marked by complex adaptations that occur to support the developing fetus and prepare the maternal body for the challenges of childbirth. These changes are orchestrated by intricate hormonal, cardiovascular, and hematologic modifications. In the context of sickle cell anemia, an inherited blood

disorder characterized by the presence of abnormal hemoglobin S, these physiological changes assume particular significance as they can interact with the underlying pathology, potentially exacerbating complications such as hemolysis [53-62]. Hormonal shifts play a pivotal role in pregnancy, with elevated levels of progesterone and estrogen influencing various physiological systems. These hormones contribute to the relaxation of smooth muscle, aiding in uterine expansion and preventing premature contractions. Additionally, hormonal changes impact the cardiovascular system, promoting increased blood flow and fluid retention, which can affect the concentration and viscosity of blood in individuals with sickle cell anemia [63-71].

Pregnancy induces significant changes in the cardiovascular system to meet the increased demands of the growing fetus. Plasma volume expands, leading to an increase in stroke volume and cardiac output. The heart rate rises, and systemic vascular resistance decreases. These adaptations aim to ensure an adequate blood supply to the developing placenta and fetus. However, in the presence of sickle cell anemia, the altered rheological properties of sickle-shaped red blood cells may contribute to challenges in blood flow dynamics [72-78]. Hematologic changes in pregnancy are multifaceted and include an increase in red blood cell mass, often termed physiological anemia of pregnancy. This adaptive response is intended to meet the increased oxygen demands of the mother and fetus. However, in individuals with sickle cell anemia, this may pose a delicate balance, as the abnormal hemoglobin S can lead to increased hemolysis and exacerbate anemia [79-86].

Pregnancy involves changes in the coagulation system to minimize the risk of hemorrhage during childbirth. Increased levels of clotting factors, particularly fibrinogen, are observed. While these changes contribute to normal hemostasis, they can potentially elevate the risk of thrombosis, a concern that may be heightened in individuals with sickle cell anemia who are already predisposed to vascular complications [87]. The immune system undergoes alterations to tolerate the presence of the developing fetus, preventing immune rejection. These changes may influence the overall inflammatory milieu and immune response. In sickle cell anemia, where inflammation is intricately linked to disease pathogenesis, understanding these immune adaptations is crucial for managing the delicate balance between immune tolerances and preventing disease exacerbation [88-91].

### Clinical Implications of Hemolysis in Pregnancy

Hemolysis during pregnancy in individuals with sickle cell anemia introduces a spectrum of clinical implications

### Management Strategies

that impact both maternal and fetal well-being. The interplay between the inherent challenges of sickle cell anemia and the dynamic physiological changes of pregnancy can lead to a heightened risk of complications. Understanding these clinical implications is crucial for healthcare providers to implement timely interventions and optimize outcomes [92,93]. Increased hemolysis in sickle cell anemia during pregnancy can contribute to the formation of sickle-shaped red blood cells, leading to vaso-occlusive crises. These painful episodes can affect various organs and result in complications such as acute chest syndrome and pain crisis, posing significant risks to maternal health [94].

Pregnancy-induced physiological anemia compounded by increased hemolysis can lead to a further decline in hemoglobin levels [95]. Severe anemia may result in fatigue, weakness, and an increased susceptibility to infections, impacting the overall health of the mother. The altered rheological properties of sickle cells, coupled with the pro-coagulant state of pregnancy, increase the risk of thrombotic events. Pregnant women with sickle cell anemia may face an elevated likelihood of venous thromboembolism, necessitating careful monitoring and prophylactic measures [96]. The combination of sickle cell anemia and increased hemolysis may predispose pregnant individuals to preeclampsia, a condition characterized by high blood pressure and organ dysfunction [97]. This complication can escalate rapidly, posing serious risks to both the mother and the fetus.

Hemolysis in pregnant women with sickle cell anemia is associated with an increased risk of preterm birth [98]. Prematurity poses significant challenges to the health and development of the fetus, requiring specialized neonatal care. The compromised oxygen-carrying capacity due to anemia and hemolysis may contribute to intrauterine growth restriction, impacting the fetal development and increasing the risk of neonatal complications. The combination of maternal complications, such as vaso-occlusive crises and preeclampsia, along with the inherent risks of sickle cell anemia, may lead to fetal distress during labor and delivery. Close monitoring and timely interventions are essential to mitigate these risks. The use of hydroxyurea, a medication that increases fetal hemoglobin production, is a potential therapeutic option [99]. However, its safety during pregnancy is a subject of ongoing research, and the balance between potential benefits and risks needs to be carefully considered. In cases of severe anemia or complications, blood transfusions may be necessary to augment oxygen delivery to both the mother and the fetus. The timing and frequency of transfusions require individualized assessment based on the clinical status of the patient.

Effectively navigating the challenges of hemolysis in pregnant individuals with sickle cell anemia requires a multifaceted approach involving close monitoring, medical interventions, and collaboration between obstetricians and hematologists. The management strategies outlined below aim to optimize maternal and fetal outcomes while mitigating the risks associated with increased hemolysis during pregnancy. Hydroxyurea, an agent that stimulates the production of fetal hemoglobin, is a potential therapeutic option. Its use in pregnancy is, however, a subject of ongoing research. The decision to initiate or continue hydroxyurea during pregnancy must weigh the potential benefits in reducing hemolysis against potential risks to fetal development. Close monitoring is crucial, and discussions between healthcare providers and patients should include a thorough assessment of individual circumstances. In cases of severe anemia or complications, blood transfusions may be indicated to improve oxygen-carrying capacity and mitigate the risks associated with increased hemolysis. The timing and frequency of transfusions should be individualized based on the patient's clinical status, hemoglobin levels, and response to other interventions. A careful balance is necessary to avoid complications associated with transfusions.

Close monitoring of hematological parameters, including hemoglobin levels, reticulocyte count, and markers of hemolysis (e.g., lactate dehydrogenase), is essential throughout pregnancy. Regular ultrasonographic assessments are crucial to monitor fetal growth, detect potential complications such as intrauterine growth restriction (IUGR), and assess amniotic fluid levels. Adequate hydration and effective pain management strategies are essential to minimize the risk and impact of vaso-occlusive crises. Educating patients on recognizing early signs of crises and the importance of prompt medical intervention can empower them to actively participate in their care [100]. Due to the increased risk of thrombotic events in pregnant individuals with sickle cell anemia, consideration of anticoagulation prophylaxis may be warranted, particularly in the presence of additional risk factors. Collaborative care involving obstetricians, hematologists, and other specialists is crucial for addressing the diverse aspects of care during pregnancy with sickle cell anemia. Developing individualized birth plans that consider the patient's hematologic status, history, and potential complications is essential for optimizing delivery outcomes. Ensuring that patients are well-informed about their condition, treatment options, and potential risks empowers them to actively participate in decision-making. Recognizing the psychosocial impact of managing sickle cell anemia during pregnancy is crucial. Providing adequate psychosocial support can positively influence the patient's

well-being and adherence to the management plan.

## Recommendations

Establish a multidisciplinary team involving obstetricians, hematologists, and genetic counselors to provide comprehensive preconception counseling.

- **Risk Assessment:** Assess the potential risks associated with pregnancy in individuals with sickle cell anemia, including the risk of hemolysis, and discuss personalized management plans. Develop individualized treatment plans that consider the patient's medical history, hematological parameters, and previous pregnancy outcomes.
- **Shared Decision-Making:** Engage in shared decision-making with patients, discussing the potential benefits and risks of available interventions, including the use of hydroxyurea and blood transfusions. Implement a schedule for regular hematological assessments throughout the pregnancy to monitor hemoglobin levels, reticulocyte count, and markers of hemolysis.
- **Prompt Intervention:** Establish clear guidelines for prompt intervention in response to changes in hematological parameters, vaso-occlusive crises, or other complications.

Evaluate the individual's thrombotic risk, considering the interplay of sickle cell anemia and pregnancy-related pro-coagulant changes.

- **Consider Anticoagulation:** Contemplate anticoagulation prophylaxis in individuals with an elevated risk of thrombotic events, balancing potential benefits and risks. Implement multimodal pain management strategies to effectively address vaso-occlusive crises while minimizing the use of opioid medications.
- **Patient Education:** Educate patients on pain management techniques and the importance of early intervention to prevent the escalation of crises. Conduct regular ultrasonographic monitoring to assess fetal growth, detect signs of intrauterine growth restriction, and evaluate amniotic fluid levels.
- **Non-Stress Tests:** Consider non-stress tests in the third trimester to assess fetal well-being and response to the uteroplacental environment. Facilitate access to patient support groups for individuals with sickle cell anemia to provide psychosocial support and share experiences.
- **Educational Resources:** Provide educational resources to patients regarding the management of sickle cell anemia during pregnancy, potential complications, and coping strategies.

Ensure a seamless transition to postpartum care, maintaining continuity between obstetric and hematological

care providers.

- **Postpartum Monitoring:** Implement a plan for postpartum monitoring of hematological parameters and potential complications, including thrombotic events. Encourage eligible individuals to participate in clinical trials and research studies focused on understanding and improving the management of hemolysis in pregnancy for individuals with sickle cell anemia.
- **Data Collection:** Contribute to the collection of real-world data to enhance the evidence base for optimal management strategies. Facilitate regular interdisciplinary meetings to discuss complex cases, share insights, and foster collaboration between obstetric and hematological care teams.
- **Patient-Centered Communication:** Prioritize clear and patient-centered communication, ensuring that individuals with sickle cell anemia are actively involved in their care decisions.

## Conclusion

Hemolysis in pregnancy for individuals with sickle cell anemia represents a unique and challenging intersection of physiological adaptations and underlying pathophysiology. The delicate balance required to navigate this complex scenario necessitates a comprehensive and individualized approach to care. In this review, we have explored the physiological changes in pregnancy, the clinical implications of hemolysis, and various management strategies that healthcare providers can employ to optimize outcomes for both the mother and the fetus. The physiological changes induced by pregnancy, including hormonal shifts, cardiovascular adaptations, and alterations in the coagulation system, set the stage for potential complications in individuals with sickle cell anemia. These changes, combined with the inherent challenges of sickle cell anemia, create a dynamic environment that demands a nuanced understanding for effective management.

Addressing hemolysis in pregnancy for individuals with sickle cell anemia requires a holistic and patient-centered perspective. By integrating physiological insights, clinical expertise, and the latest research findings, healthcare providers can navigate the complexities of this condition and strive for positive outcomes. As we move forward, the commitment to individualized care, continuous education, and the pursuit of scientific advancements will pave the way for improved management strategies and enhanced quality of life for pregnant individuals with sickle cell anemia.

## References

1. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO (2015) Sickle cell anaemia a review. *Scholars Journal of*

- Applied Medical Sciences 3(6B): 2244-52.
2. Obeagu EI (2020) Erythropoietin in Sickle Cell Anaemia A Review. *International Journal of Research Studies in Medical and Health Sciences* 5(2): 22-28.
  3. Obeagu EI (2018) Sickle Cell Anaemia: Haemolysis and Anemia. *Int J Curr Res Chem Pharm Sci* 5(10): 20-21.
  4. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, et al. (2022) An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. *J Biomed Sci* 11(10): 84.
  5. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB (2023) Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. *International Research in Medical and Health Sciences* 6(4): 12-7.
  6. Obeagu EI, Agreeen FC (2023) Anaemia among pregnant women: A review of African pregnant teenagers. *J Pub Health Nutri* 6(1): 138.
  7. Obeagu EI, Ezimah AC, Obeagu GU (2016) Erythropoietin in the anaemias of pregnancy: a review. *Int J Curr Res Chem Pharm Sci* 3(3): 10-8.
  8. Obeagu EI, Adepoju OJ, Okafor CJ, Obeagu GU, Ibekwe AM, et al. (2021) Assessment of Haematological Changes in Pregnant Women of Ido Ondo State Nigeria. *J Res Med Dent Sci Apr* 9(4): 145-8.
  9. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences* 6(2): 10-3.
  10. Jakheng SP, Obeagu EI (2022) Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri* 5 (8): 137.
  11. Singh Y, Chabra A, Venkateswaran V, Trikha A (2021) Sickle cell disease in pregnancy and anaesthetic implications A narrative review. *Journal of Obstetric Anaesthesia and Critical Care* 11(2): 70-80.
  12. Lettre G, Bauer DE (2016) Fetal haemoglobin in sickle-cell disease: from genetic epidemiology to new therapeutic strategies. *Lancet* 387(10037): 2554-64.
  13. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF (2022) Evaluation of Protein C, Protein S and Fibrinogen of Pregnant Women with Malaria in Owerri Metropolis. *Madonna University journal of Medicine and Health Sciences* 2(2): 1-9.
  14. Obeagu EI, Ikpenwa JN, Chukwueze CM, Obeagu GU. (2022) Evaluation of protein C protein S and fibrinogen of pregnant women in Owerri Metropolis. *Madonna University Journal of Medicine and Health Sciences* 2(1): 292-8.
  15. Obeagu EI, Obeagu GU, Adepoju OJ (2022) Evaluation of haematological parameters of pregnant women based on age groups in Olorunsogo road area of Ido, Ondo state. *J Bio Innov* 11(3): 936-941.
  16. Obeagu EI (2022) An update on utilization of antenatal care among pregnant Women in Nigeria. *Int J Curr Res Chem Pharm Sci* 9(9): 21-6.
  17. Okoroiwu IL, Obeagu EI, Obeagu GU (2022) Determination of clot retraction in preganant women attending antenatal clinic in federal medical centre Owerri Nigeria. *Madonna University Journal of Medicine and Health Sciences* 2(2): 91-97.
  18. Obeagu EI, Hassan AO, Adepoju OJ, Obeagu GU, Okafor CJ (2021) Evaluation of Changes in Haematological Parameters of Pregnant Women Based on Gestational Age at Olorunsogo Road Area of Ido, Ondo State Nigeria. *Journal of Research in Medical and Dental Science* 9(12): 462.
  19. Anyiam AF, Obeagu EI, Obi E, Omosigho PO, Irondi EA, et al. (2022) ABO blood groups and gestational diabetes among pregnant women attending University of Ilorin Teaching Hospital, Kwara State Nigeria. *International Journal of Research and Reports in Hematology* 5(2): 159-167.
  20. Obeagu EI (2023) Gestational Thrombocytopenia. *J Gynecol Women's Health* 25(3): 556163.
  21. Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC et al. (2022) Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology* 13(2): 26-31.
  22. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, et al (2021) Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International* 33(4): 10-19.
  23. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obsterics characteristics that effect the newborn outcomes. *Int J Adv Res Biol Sci* 10(3): 134-43.
  24. Obeagu EI, Ogunnaya FU (2023) Pregnancyinduced

- Haematological Changes: A Key To Maternal And Child Health. *European Journal of Biomedical* 10(8): 42-3.
25. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, et al. (2017) Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research* 5(4): 206.
  26. Eze RI, Obeagu EI, Edet FN (2021) Frequency of Rh Antigen C And c among pregnant women in Sub-Urban area in Eastern Nigeria. *Madonna Uni J Med Health Sci* 1(1): 19-30.
  27. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC (2023) Sick cell anaemia: a gestational enigma. *European Journal of Biomedical and Pharmaceutical Sciences* 10(9): 72-75
  28. Obeagu EI (2018) An update on micro RNA in sickle cell disease. *Int J Adv Res Biol Sci* 5(10): 157-158.
  29. Obeagu EI, Babar Q (2021) Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. *J. Clinical and Laboratory Research* 3(5): 2768-0487.
  30. Obeagu EI, Obeagu GU, Igwe MC, Alum EU, Ugwu OP (2023) Men's Essential roles in the Management of Sickle Cell Anemia. *Newport International Journal Of Scientific And Experimental Sciences* 4(2): 20-29.
  31. Obeagu EI (2023) Depression in Sickle Cell Anemia An Overlooked Battle. *Int J Curr Res Chem Pharm Sci* 10(10): 41-44.
  32. Obeagu EI, Obeagu GU (2023) Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in a Tertiary Hospital in Enugu Nigeria. *Journal of Clinical and Laboratory Research* 6(1): 2768-0487.
  33. Obeagu EI, Ofodile AC, Okwuanaso CB (2023) A review of urinary tract infections in pregnant women: Risks factors. *J Pub Health Nutri* 6(1): 26-35.
  34. Obeagu EI, Obeagu GU, Musiimenta E (2023) Post partum haemorrhage among pregnant women: Update on risks factors. *Int J Curr Res Med Sci* 9(2): 14-7.
  35. Obeagu EI, Obeagu GU, Ogunnaya FU (2023) Deep vein thrombosis in pregnancy A review of prevalence and risk factors. *Int J Curr Res Chem Pharm Sc* 10(8): 14-21.
  36. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, et al. (2022) Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis Kaduna State Nigeria. *International Journal of Research and Reports in Gynaecology* 5(3): 98-105.
  37. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA (2018) Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int J Curr Res Biol Med* 3(9): 1-4.
  38. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU (2023) Hyperthyroidism in sickle cell anaemia. *Int J Adv Res Biol Sci* 10(3): 81-89.
  39. Obeagu EI, Obeagu GU, Akinleye CA, Igwe MC (2023) Nosocomial infections in sickle cell anemia patients: Prevention through multi-disciplinary approach A review. *Medicine* 102(48): e36462.
  40. Njar VE, Ogunnaya FU, Obeagu EI Knowledge and Prevalence of the Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. *Prevalence* 5(100): 0-5.
  41. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B (2018) Expression of micro RNA 144 in sickle cell disease. *Int J Curr Res Med Sci* 4(3): 26-32.
  42. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU (2023) Anaemia in children under five years: African perspectives. *Int J Curr Res Biol Med* 1: 1-7.
  43. Onyenweaku FC, Amah HC, Obeagu EI, Nwandikor UU, Onwuasoanya UF (2017) Prevalence of asymptomatic bacteriuria and its antibiotic susceptibility pattern in pregnant women attending private ante natal clinics in Umuahia Metropolitan. *Int J Curr Res Biol Med* 2(2): 13-23.
  44. Okoroiwu IL, Chinedu-Madu JU, Obeagu EI, Vincent CC, Ochiabuto OM, et al. (2021) Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. *Journal of Pharmaceutical Research International*. 33(27A): 36-43.
  45. Obeagu EI, Njar VE, Obeagu GU (2023) Infertility Prevalence and Consequences. *Int J Curr Res Chem Pharm Sci* 10(7): 43-50.
  46. Emeka Obi OR, Ibeh NC, Obeagu EI, Okorie HM (2021) Evaluation of levels of some inflammatory cytokines in preeclamptic women in owerri. *Journal of Pharmaceutical Research International* 33(42A): 53-65.
  47. Obeagu EI, Faduma MH, Uzoma G (2023) Ectopic Pregnancy: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci* 10(4): 40-44.
  48. Obeagu EI (2018) Sickle cell anaemia: Historical

- perspective, Pathophysiology and Clinical manifestations. *Int J Curr Res Chem Pharm Sci* 5(11): 13-15.
49. Obeagu EI, Obeagu GU (2023) Sickle Cell Anaemia in Pregnancy A Review. *International Research in Medical and Health Sciences* 6(2): 10-13.
  50. Obeagu EI, Mohamod AH (2023) an update on Iron deficiency anaemia among children with congenital heart disease. *Int J Curr Res Chem Pharm Sci* 10(4): 45-48.
  51. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluation of Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital Owerri. *Madonna University journal of Medicine and Health Sciences* Mar 2(1): 218-234.
  52. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, et al. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5 Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. *Blood* 11: 16.
  53. Obeagu EI, Gamade SM, Obeagu GU. (2023) The roles of Neutrophils in pregnancy. *Int J Curr Res. Med Sci* 9(5): 31-35.
  54. Eze R, Obeagu EI, Nwakulite A, Okoroiwu IL, Vincent CC, et al. (2021) Evaluation of Copper Status and Some Red Cell Parameters of Pregnant Women in Enugu State, South Eastern Nigeria. *Journal of Pharmaceutical Research International*. 33(30A): 67-71.
  55. Obeagu EI, Obeagu GU (2023) Molar Pregnancy: Update of prevalence and risk factors. *Int J Curr Res Med Sci* 9(7): 25-28.
  56. Obeagu EI, Bunu UO (2023) Factors that influence unmet need for family planning. *International Journal of Current Research in Biology and Medicine* 8(1): 23-27.
  57. Ibebuikie JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC (2017) Barriers to utilization of maternal health services in southern senatorial district of Cross Rivers state Nigeria. *International Journal of Advanced Multidisciplinary Research* 4(8): 1-9.
  58. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K (2023) Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth* 6(1): 203-211.
  59. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA (2018) Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences* 4(9): 41-49.
  60. Obeagu EI, Obeagu GU (2023) Postpartum haemorrhage among women delivering through spontaneous vaginal delivery Prevalence and risk factors. *Int J Curr Res Chem Pharm Sci* 10(8): 22-26.
  61. Obeagu E, Eze RI, Obeagu EI, Nnatuanya IN, Dara EC. (2022) Zinc Level In Apparently Pregnant Women In Urban Area. *Madonna University journal of Medicine and Health Sciences* 2(1): 134-148.
  62. Ogomaka IA, Obeagu EI (2021) Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State Nigeria. *Journal of Pharmaceutical Research International* 33(41B): 380-386.
  63. Ifeanyi OE, Uzoma OG (2018) A review on erythropoietin in pregnancy. *J Gynecol Womens Health* 8(3): 1-4.
  64. Ifeanyi OE (2018) A Review on Pregnancy and Haematology. *Int J Curr Res Biol Med* 3(5): 26-28.
  65. Nwosu DC, Nwanjo HU, Obeagu EI, Ibebuikie JE, Ezeama MC (2015) Changes in Liver Enzymes and Lipid Profile of Pregnant Women with Malaria in Owerri, Nigeria. *International Journal of Current Research and Academic Review* 3(5): 376-383.
  66. Ibebuikie JE, Ojie CA, Nwokike GI, Obeagu EI, Nwosu DC, et al. (2017) Factors that Influence Women's Utilization of Primary Health Care Services in Calabar Cross River State, Nigeria. *Int J Curr Res Chem Pharm Sci* 4(7): 28-33.
  67. Obeagu EI (2018) Vaso-occlusion and Adhesion Molecules in Sickle Cells Disease. *Int J Curr Res Med Sci* 4(11): 33-35.
  68. Ifeanyi OE, Stella EI, Favour AA (2018) Antioxidants in the Management of Sickle Cell Anaemia. *Int J Hematol Blo Dis* 3(2): 1-2.
  69. Buhari HA, Ahmad AS, Obeagu EI (2023) Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. *Applied Sciences (NIJBAS)* 4(1).
  70. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, et al. (2015) Hcpidin and Erythropoietin Level in Sickle Cell Disease. *British Journal of Medicine and Medical Research* 8(3): 261-265.
  71. Obeagu EI (2023) Burden of Chronic Osteomyelitis: Review of Associated Factors. *Madonna University journal of Medicine and Health Sciences* 3(1): 1-6.

72. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC (2023) Sick Cell Anaemia: A Gestational Enigma. *European Journal of Biomedical and Pharmaceutical Sciences* 10(9): 72-75.
73. Ifeanyi OE, Uzoma OG (2018) A Review on Erythropoietin in Pregnancy. *J Gynecol Womens Health* 8(3): 1-4.
74. Eze R, Ezeah GA, Obeagu EI, Omeje C, Nwakulite A (2021) Evaluation of Iron Status and Some Haematological Parameters of Pregnant Women in Enugu, South Eastern Nigeria. *World Journal of Pharmaceutical and Medical Research* 7(5): 251-254.
75. Elemchukwu Q, Obeagu EI, Ochei KC (2014) Prevalence of Anaemia among Pregnant Women in Braithwaite Memorial Specialist Hospital (BMSH) Port Harcourt. *IOSR Journal of Pharmacy and Biological Sciences* 9(5): 59-64.
76. Akandinda M, Obeagu EI, Katonera MT (2022) Non-Governmental Organizations and Women's Health Empowerment in Uganda: A Review. *Asian Research Journal of Gynaecology and* 5(1): 263-267.
77. Jakheng SP, Obeagu EI, Jakheng EW, Uwakwe OS, Eze GC, et al. (2022) Occurrence of Chlamydial Infection Based on Clinical Symptoms and Clinical History among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *International Journal of Research and Reports in Gynaecology* 5(1): 222-229.
78. Gamde MS, Obeagu EI (2023) Iron Deficiency Anaemia: Enemy to Pregnancy. *European Journal of Biomedical* 10(9): 272-275.
79. Singh S, Sachdev L (2018) Effect of Maternal Haematological and Biochemical Parameters and Pregnancy Outcome. *International Journal on Recent Trends in Life Science and Mathematics* 5(2): 6-8.
80. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM (2021) Evaluation of Levels of Some Inflammatory Cytokines in Preeclamptic Women in Owerri. *Journal of Pharmaceutical Research International* 33(42A): 53-65.
81. Emeka-Obi OR, Ibeh NC, Obeagu EI, Okorie HM (2021) Studies of Some Haemostatic Variables in Preeclamptic Women in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International* 33(42B): 39-48.
82. Obeagu EI, Obeagu GU (2023) Postpartum Haemorrhage among Women Delivering through Spontaneous Vaginal Delivery: Prevalence and Risk Factors. *Int J Curr Res Chem Pharm Sci* 10(8): 22-26.
83. Obeagu EI, Obeagu GU (2023) Sick Cell Anaemia in Pregnancy: A Review. *International Research in Medical and Health Sciences* 6(2): 10-13.
84. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, et al. (2015) Antioxidant-Mediated Heinz Bodies Levels of Sick Erythrocytes under Drug-Induced Oxidative Stress. *European Journal of Biomedical and Pharmaceutical sciences* 2(1): 502-507.
85. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV Resistance in Patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)* 3(2): 56-59.
86. Obeagu EI, Bot YS, Opoku D, Obeagu GU, Hassan AO (2023) Sick Cell Anaemia: Current Burden in Africa. *International Journal of Innovative and Applied Research* 11(2): 12-14.
87. Hui C, Lili M, Libin C, Rui Z, Fang G, et al. (2012) Changes in Coagulation and Hemodynamics During Pregnancy: A Prospective Longitudinal Study of 58 Cases. *Archives of Gynecology and Obstetrics* 285: 1231-1236.
88. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN (2014) Haematological Parameters among Sick Cell Anemia Patients' State and Haemoglobin Genotype AA Individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Int J Curr Microbiol App Sci* 3(3): 1000-1005.
89. Obeagu EI, Abdirahman BF, Bunu UO, Obeagu GU (2023) Obstetrics Characteristics that Effect the Newborn Outcomes. *Int J Adv Res Biol Sci* 10(3): 134-143.
90. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of Nutritional Anaemia in Africa: A Review. *Int J Adv Res Biol Sci* 10(2): 160-163.
91. Ifeanyi E (2015) Erythropoietin (Epo) Level in Sick Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Paripex - Indian Journal of Research* 4(6): 258-259.
92. Ifeanyi OE, Stanley MC, Nwakaego OB (2014) Comparative Analysis of Some Haematological Parameters in Sick Cell Patients in Steady and Crisis State at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. *Int J Curr Microbiol App Sci* 3(3): 1046-1050.
93. Ifeanyi EO, Uzoma GO (2020) Malaria and The Sick Cell Trait: Conferring Selective Protective Advantage to Malaria. *J Clin Med Res* 2(2): 1-4.
94. Shegekar T, Pajai S (2023) A Comprehensive Review of Pregnancy in Sick Cell Disease. *Cureus* 15(6): e41165.



95. Puri M, Malhotra N (2015) Anemia in Pregnancy. Management of High-Risk Pregnancy-A Practical Approach 180.
96. Toledo SL, Guedes JV, Alpoim PN, Rios DR, Pinheiro MD (2019) Sickle Cell Disease: Hemostatic and Inflammatory Changes, and their Interrelation. Clinica Chimica Acta 493: 129-137.
97. Neligan PJ, Laffey JG (2011) Clinical Review: Special Populations-Critical Illness and Pregnancy. Crit Care 15(4): 227.
98. Silva FA, Ferreira AL, Hazin-Costa MF, Dias ML, Souza AI, et al. (2018) Adverse Clinical and Obstetric Outcomes among Pregnant Women with Different Sickle Cell Disease Genotypes. Int J Gynecol Obstet 143(1): 89-93.
99. Mc Gann PT, Ware RE (2015) Hydroxyurea Therapy for Sickle Cell Anemia. Expert Opin Drug Saf 14(11): 1749-1758.
100. Osunkwo I, Manwani D, Kanter J (2020) Current and Novel Therapies for the Prevention of Vaso-occlusive Crisis in Sickle Cell Disease. Ther Adv Hematol 11: 2040620720955000.

